European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma

• Published in: The European respiratory journal Vol. 62; no. 4; p. 2300047
• Main Authors: Papi, Alberto, Ferreira, Diogenes S, Agache, Ioana, Baraldi, Eugenio, Beasley, Richard, Brusselle, Guy, Coleman, Courtney, Gaga, Mina, Gotera Rivera, Carolina Maria, Melén, Erik, Pavord, Ian D, Peñate Gómez, Deborah, Schuermans, Daniel, Spanevello, Antonio, Tonia, Thomy, Schleich, Florence
• Format: Journal Article Web Resource
• Language: English
• Published: England European Respiratory Society 01.10.2023
• Subjects: Cardiovascular & respiratory systems; Human health sciences; Medicin och hälsovetenskap; Sciences de la santé humaine; Systèmes cardiovasculaire & respiratoire
• DOI: 10.1183/13993003.00047-2023
• ISSN: 0903-1936; 1399-3003

Recent clinical trials of as-needed fixed-dose combination of inhaled corticosteroid (ICS)/formoterol have provided new evidence that may warrant a reconsideration of current practice. A Task Force was set up by the European Respiratory Society to provide evidence-based recommendations on the use of as-needed ICS/formoterol as treatment for mild asthma. The Task Force defined two questions that were assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The Task Force utilised the outcomes to develop recommendations for a pragmatic guideline for everyday clinical practice. The Task Force suggests that adults with mild asthma use as-needed ICS/formoterol instead of regular ICS maintenance treatment plus as-needed short-acting β -antagonist (SABA) and that adolescents with mild asthma use either as-needed ICS/formoterol or ICS maintenance treatment plus as-needed SABA (conditional recommendation; low certainty of evidence). The recommendation for adults places a relatively higher value on the reduction of systemic corticosteroid use and the outcomes related to exacerbations, and a relatively lower value on the small differences in asthma control. Either treatment option is suggested for adolescent patients as the balance is very close and data more limited. The Task Force recommends that adult and adolescent patients with mild asthma use as-needed ICS/formoterol instead of as-needed SABA (strong recommendation; low certainty of evidence). This recommendation is based on the benefit of as-needed ICS/formoterol in mild asthma on several outcomes and the risks related to as-needed SABA in the absence of anti-inflammatory treatment. The implementation of this recommendation is hampered in countries (including European Union countries) where as-needed ICS/formoterol is not approved for mild asthma.